Internal Medicine Alert – February 28, 2007
February 28, 2007
View Issues
-
Payers for Performance, Beware!
With the exception of prescription of ACE inhibitors or blockers, performance measures for heart failure do not predict mortality or rehospitalization in the first 60 to 90 days after discharge. -
A Placebo-Controlled Trial of Pioglitazone in Subjects with NonAlcoholic Steatohepatitis
Until now, there has been no proven therapy for nonalcoholic steatohepatitis. Pioglitazone, known to improve insulin resistance, was shown to result in metabolic and histologic improvement in this common and potentially highly morbid malady. -
Quick Fix vs Delayed Gratification
When compared to physiotherapy and watchful waiting, corticosteroid injection in the treatment of lateral epicondylitis helps in the short term, but had the worst results at one year. -
Colonoscopic Withdrawal Times and Adenoma Detection during Screening Colonoscopy
In the setting of screening colonoscopy, longer durations of observation during withdrawal of the colonoscope were associated with higher detection rates for neoplasia. -
Estradiol Gel 0.06% (Elestrin™)
The FDA has approved an estradiol gel for the management of hot flashes associated with menopause. -
Clinical Briefs By Louis Kuritzky, MD
Elevated levels of brain natriuretic peptide (BNP) reflect cardiac ventricular wall stress, and correlate well with the presence and severity of heart failure.